# EDGAR Filing Document

**Accession Number:** 0001598599
**File Stem:** 0001104659-26-011298
**Filing Date:** 2026-2
**Character Count:** 16367
**Document Hash:** effde855dbac9c433b2d83a5a1324a35
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-011298.hdr.sgml**: 20260206

**ACCESSION NUMBER**: 0001104659-26-011298

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260206

**DATE AS OF CHANGE**: 20260206

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Innate Pharma SA
- **CENTRAL INDEX KEY:** 0001598599
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231
- **LEGAL ENTITY IDENTIFIER:** 9695002Y8420ZB8HJE29

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91173
- **FILM NUMBER:** 26605571

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 117 AVENUE DE LUMINY
- **STREET 2:** BP 30191
- **CITY:** MARSEILLE
- **NON US STATE TERRITORY:** FRANCE
- **PROVINCE COUNTRY:** I0
- **ZIP:** 13009
- **BUSINESS PHONE:** 33430303030

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 117 AVENUE DE LUMINY
- **STREET 2:** BP 30191
- **CITY:** MARSEILLE
- **NON US STATE TERRITORY:** FRANCE
- **PROVINCE COUNTRY:** I0
- **ZIP:** 13009

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Innate Pharma, SA
- **DATE OF NAME CHANGE:** 20140129
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ASTRAZENECA PLC
- **CENTRAL INDEX KEY:** 0000901832
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1 FRANCIS CRICK AVENUE
- **STREET 2:** CAMBRIDGE BIOMEDICAL CAMPUS
- **CITY:** CAMBRIDGE
- **PROVINCE COUNTRY:** X0
- **ZIP:** CB2 0AA
- **BUSINESS PHONE:** 011 44 20 7304 5000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1 FRANCIS CRICK AVENUE
- **STREET 2:** CAMBRIDGE BIOMEDICAL CAMPUS
- **CITY:** CAMBRIDGE
- **PROVINCE COUNTRY:** X0
- **ZIP:** CB2 0AA

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZENECA GROUP PLC
- **DATE OF NAME CHANGE:** 19930422

## Exhibit 99.1

**Exhibit 99.1**

**CUSIP No. 45781K105**

**<u>Schedule I</u>**

The name and present principal occupation of each of the executive officers and directors of AstraZeneca PLC are set forth below. Unless otherwise noted, each of these persons have as their business address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Name** | &nbsp;&nbsp;**Position with AstraZeneca <br> PLC** | &nbsp;&nbsp;**Principal Occupation and, if <br> not employed by <br> AstraZeneca PLC, Name, <br> Principal Business and <br> Address of Employer** | &nbsp;&nbsp;**Citizenship** |
| &nbsp;&nbsp;Anna Manz | &nbsp;&nbsp;Non-Executive Director | &nbsp;&nbsp;Chief Financial Officer, Nestlé S.A.,<br> Avenue Nestlé 55,<br> 1800 Vevey, <br> Vaud, Switzerland | &nbsp;&nbsp;British |
| &nbsp;&nbsp;Aradhana Sarin | &nbsp;&nbsp;Executive Director and Chief Financial Officer |  | &nbsp;&nbsp;American |
| &nbsp;&nbsp;Birgit Conix | &nbsp;&nbsp;Non-Executive Director |  | &nbsp;&nbsp;Belgian |
| &nbsp;&nbsp;Diana Layfield | &nbsp;&nbsp;Non-Executive Director | &nbsp;&nbsp;Chief Executive Officer Designate, Monzo Group,<br> Broadwalk House,<br> 5 Appold St, <br> London EC2A 2AG, United Kingdom | &nbsp;&nbsp;British |
| &nbsp;&nbsp;Euan Ashley | &nbsp;&nbsp;Non-Executive Director | &nbsp;&nbsp;Professor of Medicine, Genetics and Biomedical Data Science, Stanford University,<br> 450 Jane Stanford Way, <br> Stanford, CA 94305, United States | &nbsp;&nbsp;British, American |
| &nbsp;&nbsp;Karen Elizabeth Knudsen Costello | &nbsp;&nbsp;Non-Executive Director | &nbsp;&nbsp;Chief Executive Officer, Parker Institute for Cancer Immunotherapy,<br> 1 Letterman Drive, Suite D3500,<br> San Francisco, CA 94129, United States | &nbsp;&nbsp;American |
| &nbsp;&nbsp;Marcus Wallenberg | &nbsp;&nbsp;Non-Executive director | &nbsp;&nbsp;Chairman, Skandinaviska Enskilda<br> Banken,<br> Kungsträdgårdsgatan 8,<br> 106 40 Stockholm, Sweden | &nbsp;&nbsp;Swedish |
| &nbsp;&nbsp;Michel Demaré | &nbsp;&nbsp;Non-Executive Chairman of the Board |  | &nbsp;&nbsp;Belgian, Swiss |
| &nbsp;&nbsp;Pascal Soriot | &nbsp;&nbsp;Executive Director and Chief Executive Officer |  | &nbsp;&nbsp;French, Australian |
| &nbsp;&nbsp;Philip Broadley | &nbsp;&nbsp;Non-Executive director |  | &nbsp;&nbsp;British |
| &nbsp;&nbsp;Rene Haas | &nbsp;&nbsp;Non-Executive Director | &nbsp;&nbsp;Chief Executive Officer, Arm Limited,<br> 120 Rose Orchard Way,<br> San Jose, CA 95134-1358, United States | &nbsp;&nbsp;American |
| &nbsp;&nbsp;Nazneen Rahman | &nbsp;&nbsp;Non-Executive director | &nbsp;&nbsp;Chief Executive Officer, YewMaker Limited,<br> Unit 3 Upp Hall Farm,<br> Salmons Lane, Colchester, CO6 1RY, United Kingdom | &nbsp;&nbsp;British |
| &nbsp;&nbsp;Sherilyn McCoy | &nbsp;&nbsp;Non-Executive director |  | &nbsp;&nbsp;American |
| &nbsp;&nbsp;Tony Mok | &nbsp;&nbsp;Non-Executive director | &nbsp;&nbsp;Professor and Chair, Department of Clinical Oncology, The Chinese University of Hong Kong, <br> Shatin, NT, Hong Kong SAR, The People's Republic of China | &nbsp;&nbsp;Canadian |

---

**CUSIP No. 45781K105**

The name and present principal occupation of each of the executive officers and directors of MedImmune Limited are set forth below. Unless otherwise noted, each of these persons have as their business address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Name** | &nbsp;&nbsp;**Position with MedImmune<br> Limited** | &nbsp;&nbsp;**Principal Occupation and, if <br> not employed by<br> MedImmune Limited, Name,<br> Principal Business and <br> Address of Employer** | &nbsp;&nbsp;**Citizenship** |
| &nbsp;&nbsp;Alexander de Giorgio-Miller | &nbsp;&nbsp;Director | &nbsp;&nbsp;SVP Global Medical,<br> AstraZeneca\* | &nbsp;&nbsp;British |
| &nbsp;&nbsp;Aradhana Sarin | &nbsp;&nbsp;Director | &nbsp;&nbsp;Chief Financial Officer,<br> AstraZeneca\* | &nbsp;&nbsp;American |
| &nbsp;&nbsp;Caterina Brindicci | &nbsp;&nbsp;Director | &nbsp;&nbsp;SVP & Global Head Research and Development, R&I, <br> AstraZeneca\* | &nbsp;&nbsp;Italian |
| &nbsp;&nbsp;Christine Stephens | &nbsp;&nbsp;Director | &nbsp;&nbsp;Executive Director, Head of Clinical Programs & Study Operations, Early Global Development,<br> AstraZeneca\* | &nbsp;&nbsp;British |
| &nbsp;&nbsp;Elaine Harrop | &nbsp;&nbsp;Director | &nbsp;&nbsp;VP Clinical Operations, Respiratory & Immunology,<br> AstraZeneca\* | &nbsp;&nbsp;British |
| &nbsp;&nbsp;Hannah Tattersall | &nbsp;&nbsp;Director | &nbsp;&nbsp;Deputy Company Secretary,<br> AstraZeneca\* | &nbsp;&nbsp;British |
| &nbsp;&nbsp;Allistair Collins | &nbsp;&nbsp;Director | &nbsp;&nbsp;SVP Global Finance, <br> AstraZeneca\* | &nbsp;&nbsp;British |
| &nbsp;&nbsp;Lutz Jermutus | &nbsp;&nbsp;Director | &nbsp;&nbsp;VP and Head of Projects Early CVRM, <br> AstraZeneca\* | &nbsp;&nbsp;British, German |
| &nbsp;&nbsp;Matthew Bowden | &nbsp;&nbsp;Director | &nbsp;&nbsp;Company Secretary,<br> AstraZeneca\* | &nbsp;&nbsp;British |
| &nbsp;&nbsp;Pablo Panella | &nbsp;&nbsp;Director | &nbsp;&nbsp;SVP, Global Respiratory,<br> AstraZeneca\* | &nbsp;&nbsp;Italian |
| &nbsp;&nbsp;Ruud Dobber | &nbsp;&nbsp;Director | &nbsp;&nbsp;EVP Biopharmaceuticals Business,<br> AstraZeneca\* | &nbsp;&nbsp;Dutch |
| &nbsp;&nbsp;Sally Sambrook | &nbsp;&nbsp;Director | &nbsp;&nbsp;VP Clinical Operations Haematology, <br> AstraZeneca\* | &nbsp;&nbsp;British |
| &nbsp;&nbsp;Susan Galbraith | &nbsp;&nbsp;Director | &nbsp;&nbsp;Executive Vice President, Oncology Haematology R&D,<br> AstraZeneca\* | &nbsp;&nbsp;British |

---

\* Employed by AstraZeneca UK Limited

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**Innate Pharma SA**

*(Name of Issuer)*

**Ordinary Shares, EUR0.05 nominal value per share**

*(Title of Class of Securities)*

**45781K105**

*(CUSIP Number)*

**Hannah Tattersall**<br>Deputy Company Secretary<br>Eastbrook, Shaftesbury Road<br>Cambridge X0 CB2 8BF<br>44 0 20 3749 5847

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/22/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **45781K105** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**AstraZeneca PLC** | Name of reporting person<br>**AstraZeneca PLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X0** | Citizenship or place of organization<br>**X0** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**7825501.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**7825501.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**7825501.00** | Aggregate amount beneficially owned by each reporting person<br>**7825501.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**8.3%** | Percent of class represented by amount in Row (11)<br>**8.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** (1) Note to Rows 7, 9 and 11: Represents both Ordinary Shares and Ordinary Shares in the form of American Depositary Shares ("ADSs") held directly by MedImmune Limited, a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC and MedImmune Limited may each be deemed to have sole voting and dispositive power over all of the Ordinary Shares held by MedImmune Limited, whether held in the form of Ordinary Shares or ADSs.

(2) Note to Row 13: Based upon 93,719,323 Ordinary Shares of the Issuer outstanding as of December 31, 2025, as reported in the Issuer's Form 6-K filed with the Securities and Exchange Commission (the "SEC") on January 7, 2026.

| **CUSIP No.** | **45781K105** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**MedImmune Limited** | Name of reporting person<br>**MedImmune Limited** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X0** | Citizenship or place of organization<br>**X0** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**7825501.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**7825501.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**7825501.00** | Aggregate amount beneficially owned by each reporting person<br>**7825501.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**8.3%** | Percent of class represented by amount in Row (11)<br>**8.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** (1) Note to Rows 7, 9 and 11: Represents both Ordinary Shares and Ordinary Shares in the form of ADSs held directly by MedImmune Limited, a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC and MedImmune Limited may each be deemed to have sole voting and dispositive power over all of the Ordinary Shares held by MedImmune Limited, whether held in the form of Ordinary Shares or ADSs.

(2) Note to Row 13: Based upon 93,719,323 Ordinary Shares of the Issuer outstanding as of December 31, 2025, as reported in the Issuer's Form 6-K filed with the SEC on January 7, 2026.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary Shares, EUR0.05 nominal value per share

**(b) Name of Issuer:**
Innate Pharma SA

**(c) Address of Issuer's Principal Executive Offices:**
117 Avenue de Luminy, BP 30191, Marseille, I0, 13009

This Amendment No. 1 to the statement on Schedule 13D with respect to the Ordinary Shares, nominal value EUR0.05 per share, of Innate Pharma S.A., filed by the Reporting Persons on October 25, 2019 (such statement, as amended herein the "Schedule 13D"), amends the Schedule 13D as set forth herein. Except as specifically amended by this Amendment No. 1, items in the Schedule 13D remain unchanged.

**Item 5. Interest in Securities of the Issuer**

**(a)**
AstraZeneca PLC: 7,825,501 Ordinary Shares (including 1,565,001 Ordinary Shares represented by ADSs). Represents both Ordinary Shares and Ordinary Shares in the form of ADSs held directly by MedImmune Limited, a wholly-owned subsidiary of AstraZeneca PLC. Percent of class: 8.3%.

MedImmune Limited: 7,825,501 Ordinary Shares (including 1,565,001 Ordinary Shares represented by ADSs). Percent of class: 8.3%.

AstraZeneca PLC and MedImmune Limited may each be deemed to have sole voting and dispositive power over all of the Ordinary Shares held by MedImmune Limited, whether held in the form of Ordinary Shares or ADSs. Percentage ownership calculated based upon 93,719,323 Ordinary Shares of the Issuer outstanding as of December 31, 2025, as reported in the Issuer's Form 6-K filed with the SEC on January 7, 2026.

**(b)**
See the information contained in Item 5(a), which is incorporated herein by reference.

**(c)**
Neither the Reporting Persons nor any of the individuals listed on Schedule I have effected any transactions in the Ordinary Shares, including Ordinary Shares represented by ADSs during the past 60 days.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** AstraZeneca PLC

**Signature:** /s/ Matthew Bowden

**Name/Title:** Matthew Bowden / Company Secretary

**Date:** 02/06/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** MedImmune Limited

**Signature:** /s/ Matthew Bowden

**Name/Title:** Matthew Bowden / Director

**Date:** 02/06/2026